食管癌同步放化疗中50.4 Gy与60 Gy剂量的2期随机对照研究
本研究纳入97例不能手术、不可切除或复发的食管鳞癌患者,随机接受50.4 Gy/28次或60 Gy/30次放疗,同步TS-1联合奈达铂化疗。结论认为50.4 Gy仍是食管鳞癌同步放化疗的标准剂量。
要点
- 两组3级及以上毒性发生率相近(53%对51%)。
- 多因素校正后两组无进展生存与总生存差异无统计学意义。
核心结论
- 50.4 Gy仍是食管鳞癌同步放化疗的标准放疗剂量。
研究设计与样本
- 2期随机试验纳入97例不能手术、不可切除或复发的食管鳞癌患者。
- 随机分为50.4 Gy/28次/5.5周组与60 Gy/30次组,均采用累及野放疗。
- 同步化疗为每4周1周期、共2周期奈达铂80 mg/m2联合S-1 80 mg/m2。
主要发现
- 50.4 Gy组与60 Gy组3-4级毒性发生率分别为53%和51%。
- 多因素分析校正关键协变量后,两组无进展生存与总生存差异不再有统计学意义。
关键数值与推荐
- 50.4 Gy组3-4级毒性53%对60 Gy组51%。
临床怎么用
- 对接受同步TS-1联合奈达铂化疗的食管鳞癌患者,50.4 Gy可作为标准放疗剂量。
局限性
- 多因素校正后主要终点差异无统计学意义,提示组间比较需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate and compare progression-free survival (PFS) between 50.4-Gy and 60-Gy radiation doses in definitive chemoradiotherapy (CRT) for patients with esophageal cancer, and to confirm that 50.4 Gy is noninferior to the 60-Gy irradiation method in terms of PFS. METHODS AND MATERIALS: Patients with medically inoperable (including patient refusal), unresectable, and/or recurrent esophageal carcinoma referred for definitive CRT were randomly assigned to either the group receiving a total dose of 50.4 Gy in 28 fractions (1.8 Gy/d) for 5.5 weeks or the group receiving a total dose of 60 Gy in 30 fractions (2.0 Gy/d) using involved-field radiation therapy. Chemotherapy consisted of 2 courses of concurrent nedaplatin (80 mg/m2) and tegafur, gimeracil, and oteracil potassium (S-1) (80 mg/m2) in both arms every 4 weeks. The primary end point was PFS. RESULTS: Between December 2015 and February 2025, 97 patients with squamous cell carcinoma were included. Radiation treatment was completed in 98% of patients. The median follow-up time for surviving patients was 33.2 months. The 3-year PFS was 45% in the 50.4-Gy group versus 26% in the 60-Gy group (P = .017). The 3-year cumulative local control rate was 65% and 46% for the 50.4-Gy and 60-Gy groups, respectively (P = .047). The 3-year overall survival was 73% and 42% for the 50.4-Gy and 60-Gy groups, respectively (P = .018). Overall, grade 3-4 toxicities were observed in 53% of the 50.4-Gy group versus 51% of the 60-Gy group. The PFS and overall survival differences between the 50.4-Gy and 60-Gy groups were no longer statistically significant after adjustment for key covariates using multivariable analysis. CONCLUSIONS: A radiation dose of 50.4 Gy remains the standard dose in concurrent CRT for esophageal squamous cell carcinoma.
引用
- Yamashita H, Sawayanagi S, Kono M, et al. A Phase 2 Randomized Trial Comparing Radiation Doses in Concurrent Chemoradiotherapy With TS-1/Nedaplatin for Curative Treatment of Newly Diagnosed or Recurrent Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42537853. doi:10.1016/j.ijrobp.2026.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。